Abstract
BACKGROUND: Treatment options for myelofibrosis are limited. We evaluated the efficacy and safety of ruxolitinib, a potent and selective Janus kinase (JAK) 1 and 2 inhibitor, as compared with the best available therapy, in patients with myelofibrosis. METHODS: We assigned 219 patients with intermediate-2 or high-risk primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis to receive oral ruxolitinib or the best available therapy. The primary end point and key secondary end point of the study were the percentage of patients with at least a 35% reduction in spleen volume at week 48 and at week 24, respectively, as assessed with the use of magnetic resonance imaging or computed tomography. RESULTS: A total of 28% of the patients in the ruxolitinib group had at least a 35% reduction in spleen volume at week 48, as compared with 0% in the group receiving the best available therapy (P
| Original language | English |
|---|---|
| Pages (from-to) | 787-798 |
| Number of pages | 12 |
| Journal | New England Journal of Medicine |
| Volume | 366 |
| Issue number | 9 |
| DOIs | |
| Publication status | Published - Mar 1 2012 |
Fingerprint
ASJC Scopus subject areas
- Medicine(all)
Cite this
JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. / Harrison, Claire; Kiladjian, Jean Jacques; Al-Ali, Haifa Kathrin; Gisslinger, Heinz; Waltzman, Roger; Stalbovskaya, Viktoriya; McQuitty, Mari; Hunter, Deborah S.; Levy, Richard; Knoops, Laurent; Cervantes, Francisco; Vannucchi, Alessandro M.; Barbui, Tiziano; Barosi, Giovanni.
In: New England Journal of Medicine, Vol. 366, No. 9, 01.03.2012, p. 787-798.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis
AU - Harrison, Claire
AU - Kiladjian, Jean Jacques
AU - Al-Ali, Haifa Kathrin
AU - Gisslinger, Heinz
AU - Waltzman, Roger
AU - Stalbovskaya, Viktoriya
AU - McQuitty, Mari
AU - Hunter, Deborah S.
AU - Levy, Richard
AU - Knoops, Laurent
AU - Cervantes, Francisco
AU - Vannucchi, Alessandro M.
AU - Barbui, Tiziano
AU - Barosi, Giovanni
PY - 2012/3/1
Y1 - 2012/3/1
N2 - BACKGROUND: Treatment options for myelofibrosis are limited. We evaluated the efficacy and safety of ruxolitinib, a potent and selective Janus kinase (JAK) 1 and 2 inhibitor, as compared with the best available therapy, in patients with myelofibrosis. METHODS: We assigned 219 patients with intermediate-2 or high-risk primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis to receive oral ruxolitinib or the best available therapy. The primary end point and key secondary end point of the study were the percentage of patients with at least a 35% reduction in spleen volume at week 48 and at week 24, respectively, as assessed with the use of magnetic resonance imaging or computed tomography. RESULTS: A total of 28% of the patients in the ruxolitinib group had at least a 35% reduction in spleen volume at week 48, as compared with 0% in the group receiving the best available therapy (P
AB - BACKGROUND: Treatment options for myelofibrosis are limited. We evaluated the efficacy and safety of ruxolitinib, a potent and selective Janus kinase (JAK) 1 and 2 inhibitor, as compared with the best available therapy, in patients with myelofibrosis. METHODS: We assigned 219 patients with intermediate-2 or high-risk primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis to receive oral ruxolitinib or the best available therapy. The primary end point and key secondary end point of the study were the percentage of patients with at least a 35% reduction in spleen volume at week 48 and at week 24, respectively, as assessed with the use of magnetic resonance imaging or computed tomography. RESULTS: A total of 28% of the patients in the ruxolitinib group had at least a 35% reduction in spleen volume at week 48, as compared with 0% in the group receiving the best available therapy (P
UR - http://www.scopus.com/inward/record.url?scp=84857837774&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84857837774&partnerID=8YFLogxK
U2 - 10.1056/NEJMoa1110556
DO - 10.1056/NEJMoa1110556
M3 - Article
C2 - 22375970
AN - SCOPUS:84857837774
VL - 366
SP - 787
EP - 798
JO - New England Journal of Medicine
JF - New England Journal of Medicine
SN - 0028-4793
IS - 9
ER -